ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
Portfolio Pulse from
ImmunityBio, Inc. announced that the European Medicines Agency has accepted the marketing authorization application for ANKTIVA, a treatment for BCG-unresponsive non-muscle invasive bladder cancer. This marks a significant step in the approval process for the drug in Europe.
January 27, 2025 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ImmunityBio's ANKTIVA has been accepted for review by the European Medicines Agency, marking a significant step towards potential approval in Europe for treating BCG-unresponsive bladder cancer.
The acceptance of the marketing authorization application by the EMA is a crucial step towards the potential approval of ANKTIVA in Europe. This development could positively impact ImmunityBio's stock as it represents progress in expanding the drug's market reach.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100